Pharma BD Deal Intelligence
Gilead Sciences Inc. / CymaBay Therapeutics
2024 · Acquisition/Merger · $4.4B · Complete
Announcement Sentiment
86
Strongly positive
Outcome Score
76
Worked — the deal delivered on its rationale.
Gilead acquired CymaBay for $4.4B for seladelpar for primary biliary cholangitis.
Key facts
- Announced Feb 12, 2024
- Closed Mar 22, 2024
- Deal value $4.4B
- Deal type Acquisition/Merger
- Therapeutic area Hepatology
- Key assets seladelpar
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals